varthamana2
Ассоциации
santen
oftalmolog_club
Шахматы
www.worldglaucoma.org
Торика
Beaver
appstore
Основные мероприятия ассоциации офтальмологов
ВК
bannerparasol
askin_heid
Конгресс
Mobile
АйНьюс.РФ
facebook
eye5
YouTube
medlab
Первая пятница декабря
Флаги
glaucoma_net_ru
Конгресс 2014
профессор
Новости офтальмологии
We reviewed the current literature on the ability of micro-perimetry to detect non-neovascular age-related macular degeneration (AMD) disease progression. The index test was retinal sensitivity mea-surement assessed by microperimetry and comparators were other func-tional measures (best-corrected and low-luminance visual acuities, and fixation stability) and structural parameters [retinal thickness, choroidal thickness, and area of geographic atrophy (GA) determined by color fun-dus photographs, short-wave or near-infrared fundus autofluorescence].
Для начисления зачетных единиц, полученных после прохождения обучения в рамках учебного мероприятия (конференция, мастер-класс, заседание профессионального общества), Вам необходимо указать индивидуальный код подтверждения на сайте Координационного совета по развитию непрерывного медицинского и фармацевтического образования Министерства здравоохранения РФ: http://www.sovetnmo.ru.
Рекомендации детально объясняют публикационный процесс, процедуры рецензирования и опубликования, а также общепринятые требования к структуре научной статьи. Данная информация нацелена на помощь научным работникам и повышение их публикационной активности.
Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to stop or slow disease progression. Current glaucoma medications achieve this almost exclusively through reduction of intraocular pressure (IOP). Unfortunately, even with appropriate use of currently available medications, many people with glaucoma will still experience vision loss. Intraocular pressure is the only known modifiable risk factor for patients with glaucoma, so improvements in patient outcomes rely on tight IOP control and patient adherence to therapy. In this educational activity, leading clinicians review established and new therapeutic agents for patients with glaucoma, including the recent clinical evidence for their safety and efficacy. In addition, discussion will comprise the recent evidence concerning the effects of low perfusion pressure on glaucoma development and progression.
Management of the geographic atrophy seen in late-stage dry age-related macular degeneration (AMD) poses several challenges. Scientific understanding of geographic atrophy continues to develop, and recent changes have been made to how this condition is classified, which underscores the importance of accurately monitoring progression. Although no treatment has been approved to manage late-stage dry AMD, complement inhibition, visual cycle modulation, neuroprotection, and stem cell therapy have had encouraging results in clinical trials
Purpose: To systematically review anatomical and functional outcomes subsequent to switching from bevacizumab/ranibizumab to aflibercept monotherapy in patients with treatment-resistant neovascular age-related macular degeneration (nAMD).
GenSight Biologics reported sustained visual acuity improvement in patients with Leber’s hereditary optic neuropathy who were treated with GS010 in a phase 1/2 clinical trial
Overview Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to stop or slow disease progression. Current glaucoma medications achieve this almost exclusively through reduction of intraocular pressure (IOP). Unfortunately, even with appropriate use of currently available medications, many people with glaucoma will still experience vision loss. Intraocular pressure is the only known modifiable risk factor for patients with glaucoma, so improvements in patient outcomes rely on tight IOP control and patient adherence to therapy. In this educational activity, leading clinicians review established and new therapeutic agents for patients with glaucoma, including the recent clinical evidence for their safety and efficacy. In addition, discussion will comprise the recent evidence concerning the effects of low perfusion pressure on glaucoma development and progression
A 25-year-old woman with myopia who had an AC pIOL implantation in the left eye and posterior chamber pIOL implantation in the right eye developed bilateral granulomatous panuveitis 2 months after the second surgery. Physical examination showed bilateral Koeppe and Busacca nodules. Fluorescein angiography showed diffuse vascular and retinal pigment epithelial leakage in both eyes. With assessment of sympathetic ophthalmia, treatment with a high-dose systemic steroid was started. Oral cyclosporine and azathioprine were later added.
1. Лечащий врач по согласованию с руководителем медорганизации может отказаться лечить пациента, если отказ не угрожает жизни больного 2. Решение об отказе нужно передать пациенту либо отправить заказным письмом с уведомлением 3. Если все врачи отказались от наблюдения пациента по предусмотренной законом процедуре, руководитель может предложить гражданину обратиться в иную медорганизацию
Purpose: The aim was to evaluate the safety of bilateral same-day injections with intravitreal antiangiogenic drugs for macular diseases. Methods: Cross-sectional retrospective review of unilateral and bilateral same-day antiangiogenic injections was conducted between January 2011 and March 2016 in the Unit of Macula, University and Polytechnic Hospital La Fe (Valencia, Spain). A total of 8,172 injections were administered, among which 6,560 were unilateral and 1,612 were bilateral injections. Patients were included in the study regardless of the diagnosis. Ranibizumab and aflibercept were the antiangiogenic drugs used. The presence of endophthalmitis or retinal detachment was evaluated.
А что Вы думаете по этому поводу?
The Scientific Committee invites you to participate actively in this congress which will be an extraordinary occasion for the exchange of thoughts and experiences. We look forward to receiving abstracts for consideration and inclusion in the program as oral or poster presentations.
Fusing the embryos of mice, where one contains a marker of its lineage, is a well-established technique in developmental biology research. The stripy corneas were still a surprise, though…
The Scientific Committee invites you to participate actively in this congress which will be an extraordinary occasion for the exchange of thoughts and experiences. We look forward to receiving abstracts for consideration and inclusion in the program as oral or poster presentations
The International Committee of Medical Journal Editors has updated the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. The updated Recommendations may be found and downloaded at www.icmje.org. To assist in identifying where changes have been made, an annotated copy of the Recommendations is available at our website under “News & Editorials.”
Inder Paul Singh, MD, says the iStent (Glaukos) helps physicians reduce medication burden. He provides details on outcomes and discusses why safety makes this device advantageous for surgeons. Dr. Singh also explains how the iStent has improved the overall efficiency of his cataract surgery cases
Голосование
Что "заставляет" Вас заниматься научными исследованиями?
Популярная пресса
Фотогалерея
Интересное видео
Книги-новинки
Клуб молодых офтальмологов

МОО "Глаукомное общество"

Экспертный совет по глаукоме

Школа офтальмолога

Новостная лента на Twitter
Новости зарубежной офтальмологии